- CO.20 Study
A Phase III Randomised Study of Brivanib Alaninate (BMS- 582664) in Combination with Cetuximab (ERBITUX®) Versus Placebo in Combination with Cetuximab (ERBITUX®) in Patients With K-Ras Wild Type Tumours Previously Treated with Combination Chemotherapy for Metastatic Colorectal Carcinoma.
Purpose of the Study
The purpose of this study was to find out whether it is better to receive a new drug, brivanib, in combination with cetuximab, or better to receive only cetuximab for colon or rectal cancer.
A/Prof Jeremy Shapiro
DETAILED INFORMATION AVAILABLE
Available online at ClinicalTrials.Gov here
- Ringash J, Au HJ, Siu LL, Shapiro JD, Jonker DJ, Zalcberg JR, Moore MJ, Strickland A, Kotb R, Jeffery M, Alcindor T, Ng S, Salim M, Sabesan S, Easaw JC, Shannon J, El-Tahche F, Walters I, Tu D, O’Callaghan CJ, NCIC Clinical Trials Group, Australasian Gastrointestinal Trials Group. Quality of life in patients with K-RAS wild-type colorectal cancer: the CO.20 phase 3 randomized trial. Cancer 2014; 120(2): 181–189.
- Siu L, Shapiro J, Jonker D, Karapetis C, Zalcberg J, Simes J, Couture F, Moore M, Price T, Siddiqui J, Nott L, Charpentier D, Liauw W, Sawyer M, Jefford M, Magoski N, Haydon A, Walters I, Ringash J, Tu D, O’Callaghan C. Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 trial. Journal of Clinical Oncology; 31(19): 2477-2484.
The purpose of this study is to find out whether it is better to receive a new drug, brivanib, in combination with cetuximab, or better to receive only cetuximab for colon or rectal cancer.
Dr Jeremy Shapiro, Medical Oncologist, Cabrini Health VIC